<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36981522</PMID><DateRevised><Year>2023</Year><Month>03</Month><Day>31</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2227-9032</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><Issue>6</Issue><PubDate><Year>2023</Year><Month>Mar</Month><Day>16</Day></PubDate></JournalIssue><Title>Healthcare (Basel, Switzerland)</Title><ISOAbbreviation>Healthcare (Basel)</ISOAbbreviation></Journal><ArticleTitle>A Case Study of Successful Application of the Principles of ME/CFS Care to an Individual with Long COVID.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">865</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/healthcare11060865</ELocationID><Abstract><AbstractText>Persistent fatigue is one of the most common symptoms of post-COVID conditions, also termed long COVID. At the extreme end of the severity spectrum, some individuals with long COVID also meet the criteria for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), raising the possibility that symptom management approaches for ME/CFS may benefit some long COVID patients. We describe the long-term outcomes of a 19-year-old male who developed profound impairment consistent with ME/CFS after a SARS-CoV-2 infection early in the pandemic. We evaluated and treated him using our clinic's approach to ME/CFS. This included a history and physical examination that ascertained joint hypermobility, pathological reflexes, physical therapy maneuvers to look for a range of motion restrictions in the limbs and spine, orthostatic testing, and screening laboratory studies. He was found to have profound postural tachycardia syndrome, several ranges of motion restrictions, and mast cell activation syndrome. He was treated according to our clinic's guidelines for managing ME/CFS, which included manual physical therapy maneuvers and both non-pharmacologic measures and medications directed at postural tachycardia syndrome and mast cell activation. He experienced significant improvement in his symptoms over 30 months. His case emphasizes how the application of the principles of treating ME/CFS has the potential to provide a direction for treating long COVID.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Petracek</LastName><ForeName>Lindsay S</ForeName><Initials>LS</Initials><AffiliationInfo><Affiliation>The Division of Adolescent and Young Adult Medicine, Department of Pediatrics, Johns Hopkins University School of Medicine Baltimore, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Broussard</LastName><ForeName>Camille A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>The Division of Adolescent and Young Adult Medicine, Department of Pediatrics, Johns Hopkins University School of Medicine Baltimore, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Swope</LastName><ForeName>Renee L</ForeName><Initials>RL</Initials><AffiliationInfo><Affiliation>The Division of Adolescent and Young Adult Medicine, Department of Pediatrics, Johns Hopkins University School of Medicine Baltimore, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rowe</LastName><ForeName>Peter C</ForeName><Initials>PC</Initials><Identifier Source="ORCID">0000-0002-3586-2677</Identifier><AffiliationInfo><Affiliation>The Division of Adolescent and Young Adult Medicine, Department of Pediatrics, Johns Hopkins University School of Medicine Baltimore, Baltimore, MD 21205, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Healthcare (Basel)</MedlineTA><NlmUniqueID>101666525</NlmUniqueID><ISSNLinking>2227-9032</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">adolescent</Keyword><Keyword MajorTopicYN="N">chronic fatigue syndrome</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">myalgic encephalomyelitis</Keyword><Keyword MajorTopicYN="N">orthostatic intolerance</Keyword><Keyword MajorTopicYN="N">post COVID-19 condition</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>3</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>29</Day><Hour>1</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>3</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36981522</ArticleId><ArticleId IdType="pmc">PMC10048325</ArticleId><ArticleId IdType="doi">10.3390/healthcare11060865</ArticleId><ArticleId IdType="pii">healthcare11060865</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Carf&#xec; A., Bernabei R., Landi F. Group ftGAC-P-ACS. Persistent Symptoms in Patients After Acute COVID-19. JAMA. 2020;324:603&#x2013;605. doi: 10.1001/jama.2020.12603.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12603</ArticleId><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Nath A. Long-Haul COVID. Neurology. 2020;95:559&#x2013;560. doi: 10.1212/WNL.0000000000010640.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000010640</ArticleId><ArticleId IdType="pubmed">32788251</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization  A Clinical Case Definition of Post COVID-19 Condition by a Delphi Consensus. World Health Organization.  [(accessed on 30 December 2022)].  Available online:  https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1.</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention  Post-COVID Conditions: Information for Healthcare Providers. Updated 9 July 2021.  [(accessed on 30 December 2021)]; Available online:  https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-conditions.html.</Citation></Reference><Reference><Citation>Kedor C., Freitag H., Meyer-Arndt L., Wittke K., Hanitsch L.G., Zoller T., Steinbeis F., Haffke M., Rudolf G., Heidecker B., et al. A prospective observational study of post-COVID-19 chronic fatigue syndrome following the first pandemic wave in Germany and biomarkers associated with symptom severity. Nat. Commun. 2022;13:5104. doi: 10.1038/s41467-022-32507-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-32507-6</ArticleId><ArticleId IdType="pmc">PMC9426365</ArticleId><ArticleId IdType="pubmed">36042189</ArticleId></ArticleIdList></Reference><Reference><Citation>Petracek L.S., Suskauer S.J., Vickers R.F., Patel N.R., Violand R.L., Swope R.L., Rowe P.C. Adolescent and Young Adult ME/CFS After Confirmed or Probable COVID-19. Original Research. Front. Med. 2021;8:668944. doi: 10.3389/fmed.2021.668944.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.668944</ArticleId><ArticleId IdType="pmc">PMC8116546</ArticleId><ArticleId IdType="pubmed">33996867</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunt J., Blease C., Geraghty K.J. Long Covid at the crossroads: Comparisons and lessons from the treatment of patients with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) J. Health Psychol. 2022;27:3106&#x2013;3120. doi: 10.1177/13591053221084494.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/13591053221084494</ArticleId><ArticleId IdType="pubmed">35341334</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso M.J., Deveau T.-M., Munter S.E., Ryder D.M., Buck A.M., Beck-Engeser G., Chan F., Lu S., Goldberg S.A., Hoh R., et al. Chronic viral coinfections differentially affect the likelihood of developing long COVID. J. Clin. Investig. 2023;133:e163669. doi: 10.1172/JCI163669.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI163669</ArticleId><ArticleId IdType="pmc">PMC9888380</ArticleId><ArticleId IdType="pubmed">36454631</ArticleId></ArticleIdList></Reference><Reference><Citation>Notarte K.I., de Oliveira M.H., Peligro P.J., Velasco J.V., Macaranas I., Ver A.T., Fern&#xe1;ndez-de-Las-Pe&#xf1;as C. Age, Sex and Previous Comorbidities as Risk Factors Not Associated with SARS-CoV-2 Infection for Long COVID-19: A Systematic Review and Meta-Analysis. J. Clin. Med. 2022;11:7314. doi: 10.3390/jcm11247314.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11247314</ArticleId><ArticleId IdType="pmc">PMC9787827</ArticleId><ArticleId IdType="pubmed">36555931</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis H.E., McCorkell L., Vogel J.M., Topol E.J. Long COVID: Major findings, mechanisms and recommendations. Nat. Rev. Microbiol. 2023;21:133&#x2013;146. doi: 10.1038/s41579-022-00846-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Committee on the Diagnostic Criteria for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, Board on the Health of Select Populations, Institute of Medicine . Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness. National Academies Press (US); Washington, DC, USA: 2015. The National Academies Collection: Reports funded by National Institutes of Health.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowe P.C., Marden C.L., Flaherty M.A., Jasion S.E., Cranston E.M., Johns A.S., Fan J., Fontaine K.R., Violand R.L. Impaired Range of Motion of Limbs and Spine in Chronic Fatigue Syndrome. J. Pediatr. 2014;165:360&#x2013;366. doi: 10.1016/j.jpeds.2014.04.051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpeds.2014.04.051</ArticleId><ArticleId IdType="pubmed">24929332</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowe P.C., Underhill R.A., Friedman K.J., Gurwitt A., Medow M.S., Schwartz M.S., Speight N., Stewart J.M., Vallings R., Rowe K.S. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Diagnosis and Management in Young People: A Primer. Review. Front. Pediatr. 2017;5:121. doi: 10.3389/fped.2017.00121.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fped.2017.00121</ArticleId><ArticleId IdType="pmc">PMC5474682</ArticleId><ArticleId IdType="pubmed">28674681</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowe P.C., Marden C.L., Heinlein S., Edwards C.C. Improvement of severe myalgic encephalomyelitis/chronic fatigue syndrome symptoms following surgical treatment of cervical spinal stenosis. J. Transl. Med. 2018;16:21. doi: 10.1186/s12967-018-1397-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-018-1397-7</ArticleId><ArticleId IdType="pmc">PMC5796598</ArticleId><ArticleId IdType="pubmed">29391028</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowe P.C., Bou-Holaigah I., Kan J.S., Calkins H. Is neurally mediated hypotension an unrecognised cause of chronic fatigue? Lancet. 1995;345:623&#x2013;624. doi: 10.1016/S0140-6736(95)90525-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(95)90525-1</ArticleId><ArticleId IdType="pubmed">7898182</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowe P.C., Fontaine K.R., Lauver M., Jasion S.E., Marden C.L., Moni M., Thompson C.B., Violand R.L. Neuromuscular Strain Increases Symptom Intensity in Chronic Fatigue Syndrome. PLoS ONE. 2016;11:e0159386. doi: 10.1371/journal.pone.0159386.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0159386</ArticleId><ArticleId IdType="pmc">PMC4948885</ArticleId><ArticleId IdType="pubmed">27428358</ArticleId></ArticleIdList></Reference><Reference><Citation>Roma M., Marden C.L., De Wandele I., Francomano C.A., Rowe P.C. Postural tachycardia syndrome and other forms of orthostatic intolerance in Ehlers-Danlos syndrome. Auton. Neurosci. Basic Clin. 2018;215:89&#x2013;96. doi: 10.1016/j.autneu.2018.02.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autneu.2018.02.006</ArticleId><ArticleId IdType="pubmed">29519641</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowe P.C., Marden C.L., Flaherty M.A., Jasion S.E., Cranston E.M., Fontaine K.R., Violand R.L. Two-Year Follow-Up of Impaired Range of Motion in Chronic Fatigue Syndrome. J. Pediatr. 2018;200:249&#x2013;253.e1. doi: 10.1016/j.jpeds.2018.05.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpeds.2018.05.012</ArticleId><ArticleId IdType="pubmed">29866593</ArticleId></ArticleIdList></Reference><Reference><Citation>Straus S.E., Dale J.K., Tobi M., Lawley T., Preble O., Blaese R.M., Hallahan C., Henle W. Acyclovir treatment of the chronic fatigue syndrome. Lack of efficacy in a placebo-controlled trial. N. Engl. J. Med. 1988;319:1692&#x2013;1698. doi: 10.1056/NEJM198812293192602.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM198812293192602</ArticleId><ArticleId IdType="pubmed">2849717</ArticleId></ArticleIdList></Reference><Reference><Citation>Barron D.F., Cohen B.A., Geraghty M.T., Violand R., Rowe P.C. Joint hypermobility is more common in children with chronic fatigue syndrome than in healthy controls. J. Pediatr. 2002;141:421&#x2013;425. doi: 10.1067/mpd.2002.127496.</Citation><ArticleIdList><ArticleId IdType="doi">10.1067/mpd.2002.127496</ArticleId><ArticleId IdType="pubmed">12219066</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowe P., Fontaine K., Violand R. Neuromuscular strain as a contributor to cognitive and other symptoms in chronic fatigue syndrome: Hypothesis and conceptual model. Hypothesis and Theory. Front. Physiol. 2013;4:115. doi: 10.3389/fphys.2013.00115.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphys.2013.00115</ArticleId><ArticleId IdType="pmc">PMC3655286</ArticleId><ArticleId IdType="pubmed">23720638</ArticleId></ArticleIdList></Reference><Reference><Citation>Henderson F.C., Rosenbaum R., Narayanan M., Koby M., Tuchman K., Rowe P.C., Francomano C. Atlanto-axial rotary instability (Fielding type 1): Characteristic clinical and radiological findings, and treatment outcomes following alignment, fusion, and stabilization. Neurosurg. Rev. 2020;44:1553&#x2013;1568. doi: 10.1007/s10143-020-01345-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10143-020-01345-9</ArticleId><ArticleId IdType="pmc">PMC8121728</ArticleId><ArticleId IdType="pubmed">32623537</ArticleId></ArticleIdList></Reference><Reference><Citation>Henderson F. Cranio-cervical Instability in Patients with Hypermobility Connective Disorders. J. Spine. 2016;5:299. doi: 10.4172/2165-7939.1000299.</Citation><ArticleIdList><ArticleId IdType="doi">10.4172/2165-7939.1000299</ArticleId></ArticleIdList></Reference><Reference><Citation>Petracek L.S., Rowe Peter C. Orthostatic Intolerance and Chiari I Malformation. In: Limbrick D.D., Leonard J., editors. Chiari I Malformation, an Issue of Neurosurgery Clinics of North America. Vol. 34 Elsevier Health Sciences; Amsterdam, The Netherlands: Clinics in Surgery; Cheyenne, WY, USA: 2023.</Citation><ArticleIdList><ArticleId IdType="pubmed">36424063</ArticleId></ArticleIdList></Reference><Reference><Citation>Malanga G.A., Landes P., Nadler S.F. Provocative tests in cervical spine examination: Historical basis and scientific analyses. Pain Physician. 2003;6:199&#x2013;205. doi: 10.36076/ppj.2003/6/199.</Citation><ArticleIdList><ArticleId IdType="doi">10.36076/ppj.2003/6/199</ArticleId><ArticleId IdType="pubmed">16883381</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart J.M., Gewitz M.H., Weldon A., Arlievsky N., Li K., Munoz J. Orthostatic Intolerance in Adolescent Chronic Fatigue Syndrome. Pediatrics. 1999;103:116&#x2013;121. doi: 10.1542/peds.103.1.116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.103.1.116</ArticleId><ArticleId IdType="pubmed">9917448</ArticleId></ArticleIdList></Reference><Reference><Citation>Roma M., Marden C.L., Rowe P.C. Passive standing tests for the office diagnosis of postural tachycardia syndrome: New methodological considerations. Fatigue Biomed. Health Behav. 2018;6:179&#x2013;192. doi: 10.1080/21641846.2018.1512836.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21641846.2018.1512836</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyatt K.H., Jacobson L.B., Schneider V.S. Comparison of 70 degrees tilt, LBNP, and passive standing as measures of orthostatic tolerance. Aviat Space Env. Med. 1975;46:801&#x2013;808.</Citation><ArticleIdList><ArticleId IdType="pubmed">1156287</ArticleId></ArticleIdList></Reference><Reference><Citation>Freeman R., Wieling W., Axelrod F.B., Benditt D.G., Benarroch E., Biaggioni I., Cheshire W.P., Chelimsky T., Cortelli P., Gibbons C.H., et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin. Auton. Res. 2011;21:69&#x2013;72. doi: 10.1007/s10286-011-0119-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10286-011-0119-5</ArticleId><ArticleId IdType="pubmed">21431947</ArticleId></ArticleIdList></Reference><Reference><Citation>Afrin L.B., Ackerley M.B., Bluestein L.S., Brewer J.H., Brook J.B., Buchanan A.D., Cuni J.R., Davey W.P., Dempsey T.T., Dorff S.R., et al. Diagnosis of mast cell activation syndrome: A global &#x201c;consensus-2&#x201d;. Diagnosis. 2020;8:137&#x2013;152. doi: 10.1515/dx-2020-0005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/dx-2020-0005</ArticleId><ArticleId IdType="pubmed">32324159</ArticleId></ArticleIdList></Reference><Reference><Citation>Wieling W., van Lieshout J.J., van Leeuwen A.M. Physical manoeuvres that reduce postural hypotension in autonomic failure. Clin. Auton. Res. 1993;3:57&#x2013;65. doi: 10.1007/BF01819146.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF01819146</ArticleId><ArticleId IdType="pubmed">8477182</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibao C., Arzubiaga C., Roberts I.L.J., Raj S., Black B., Harris P., Biaggioni I. Hyperadrenergic Postural Tachycardia Syndrome in Mast Cell Activation Disorders. Hypertension. 2005;45:385&#x2013;390. doi: 10.1161/01.HYP.0000158259.68614.40.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.HYP.0000158259.68614.40</ArticleId><ArticleId IdType="pubmed">15710782</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyons J.J., Yu X., Hughes J.D., Le Q.T., Jamil A., Bai Y., Ho N., Zhao M., Liu Y., O&#x2019;Connell M.P., et al. Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number. Nat. Genet. 2016;48:1564&#x2013;1569. doi: 10.1038/ng.3696.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3696</ArticleId><ArticleId IdType="pmc">PMC5397297</ArticleId><ArticleId IdType="pubmed">27749843</ArticleId></ArticleIdList></Reference><Reference><Citation>Theoharides T.C., Valent P., Akin C. Mast Cells, Mastocytosis, and Related Disorders. N. Engl. J. Med. 2015;373:163&#x2013;172. doi: 10.1056/NEJMra1409760.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1409760</ArticleId><ArticleId IdType="pubmed">26154789</ArticleId></ArticleIdList></Reference><Reference><Citation>Afrin L.B., Weinstock L.B., Molderings G.J. Covid-19 hyperinflammation and post-Covid-19 illness may be rooted in mast cell activation syndrome. Int. J. Infect. Dis. 2020;100:327&#x2013;332. doi: 10.1016/j.ijid.2020.09.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.09.016</ArticleId><ArticleId IdType="pmc">PMC7529115</ArticleId><ArticleId IdType="pubmed">32920235</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinstock L.B., Brook J.B., Walters A.S., Goris A., Afrin L.B., Molderings G.J. Mast cell activation symptoms are prevalent in Long-COVID. Int. J. Infect. Dis. 2021;112:217&#x2013;226. doi: 10.1016/j.ijid.2021.09.043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2021.09.043</ArticleId><ArticleId IdType="pmc">PMC8459548</ArticleId><ArticleId IdType="pubmed">34563706</ArticleId></ArticleIdList></Reference><Reference><Citation>Theoharides T.C., Kempuraj D. Role of SARS-CoV-2 Spike-Protein-Induced Activation of Microglia and Mast Cells in the Pathogenesis of Neuro-COVID. Cells. 2023;12:688. doi: 10.3390/cells12050688.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells12050688</ArticleId><ArticleId IdType="pmc">PMC10001285</ArticleId><ArticleId IdType="pubmed">36899824</ArticleId></ArticleIdList></Reference><Reference><Citation>Glynne P., Tahmasebi N., Gant V., Gupta R. Long COVID following mild SARS-CoV-2 infection: Characteristic T cell alterations and response to antihistamines. J. Investig. Med. 2022;70:61&#x2013;67. doi: 10.1136/jim-2021-002051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jim-2021-002051</ArticleId><ArticleId IdType="pmc">PMC8494538</ArticleId><ArticleId IdType="pubmed">34611034</ArticleId></ArticleIdList></Reference><Reference><Citation>Molderings G.J., Zienkiewicz T., Homann J., Menzen M., Afrin L.B. Risk of solid cancer in patients with mast cell activation syndrome: Results from Germany and USA. F1000Research. 2017;6:1889. doi: 10.12688/f1000research.12730.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/f1000research.12730.1</ArticleId><ArticleId IdType="pmc">PMC5710302</ArticleId><ArticleId IdType="pubmed">29225779</ArticleId></ArticleIdList></Reference><Reference><Citation>Polo O., Pesonen P., Tuominen E. Low-dose naltrexone in the treatment of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) Fatigue Biomed. Health Behav. 2019;7:207&#x2013;217. doi: 10.1080/21641846.2019.1692770.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21641846.2019.1692770</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabanas H., Muraki K., Staines D., Marshall-Gradisnik S. Naltrexone Restores Impaired Transient Receptor Potential Melastatin 3 Ion Channel Function in Natural Killer Cells From Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients. Front. Immunol. 2019;10:2545. doi: 10.3389/fimmu.2019.02545.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.02545</ArticleId><ArticleId IdType="pmc">PMC6834647</ArticleId><ArticleId IdType="pubmed">31736966</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabanas H., Muraki K., Eaton-Fitch N., Staines D.R., Marshall-Gradisnik S. Potential Therapeutic Benefit of Low Dose Naltrexone in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Role of Transient Receptor Potential Melastatin 3 Ion Channels in Pathophysiology and Treatment. Front. Immunol. 2021;12:687806. doi: 10.3389/fimmu.2021.687806.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.687806</ArticleId><ArticleId IdType="pmc">PMC8313851</ArticleId><ArticleId IdType="pubmed">34326841</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones M.R., Prabhakar A., Viswanath O., Urits I., Green J.B., Kendrick J.B., Brunk A.J., Eng M.R., Orhurhu V., Cornett E.M., et al. Thoracic Outlet Syndrome: A Comprehensive Review of Pathophysiology, Diagnosis, and Treatment. Pain Ther. 2019;8:5&#x2013;18. doi: 10.1007/s40122-019-0124-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40122-019-0124-2</ArticleId><ArticleId IdType="pmc">PMC6514035</ArticleId><ArticleId IdType="pubmed">31037504</ArticleId></ArticleIdList></Reference><Reference><Citation>Oz&#xe7;akar L., Ertan H., Kaymak B. Two cases and two particular signs of thoracic outlet syndrome: Tremor and tachycardia. Rheumatol. Int. 2008;29:227&#x2013;228. doi: 10.1007/s00296-008-0629-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-008-0629-1</ArticleId><ArticleId IdType="pubmed">18551294</ArticleId></ArticleIdList></Reference><Reference><Citation>Knuttinen M.-G., Zurcher K.S., Khurana N., Patel I., Foxx-Orenstein A., Harris L.A., Lawrence A., Aguilar F., Sichlau M., Smith B.H., et al. Imaging findings of pelvic venous insufficiency in patients with postural orthostatic tachycardia syndrome. Phlebology. 2021;36:32&#x2013;37. doi: 10.1177/0268355520947610.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0268355520947610</ArticleId><ArticleId IdType="pubmed">32757696</ArticleId></ArticleIdList></Reference><Reference><Citation>Venbrux A.C., Lambert D.L. Embolization of the ovarian veins as a treatment for patients with chronic pelvic pain caused by pelvic venous incompetence (pelvic congestion syndrome) Curr. Opin. Obstet. Gynecol. 1999;11:395&#x2013;399. doi: 10.1097/00001703-199908000-00006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00001703-199908000-00006</ArticleId><ArticleId IdType="pubmed">10498026</ArticleId></ArticleIdList></Reference><Reference><Citation>Venbrux A.C., Chang A.H., Kim H.S., Montague B.J., Hebert J.B., Arepally A., Rowe P.C., Barron D.F., Lambert D., Robinson J.C. Pelvic congestion syndrome (pelvic venous incompetence): Impact of ovarian and internal iliac vein embolotherapy on menstrual cycle and chronic pelvic pain. J. Vasc. Interv. Radiol. 2002;13:171&#x2013;178. doi: 10.1016/S1051-0443(07)61935-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1051-0443(07)61935-6</ArticleId><ArticleId IdType="pubmed">11830623</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan S.D., Hanauer J., Rowe P.C., Barron D.F., Darbari A., Oliva-Hemker M. Gastrointestinal symptoms associated with orthostatic intolerance. J. Pediatr. Gastroenterol. Nutr. 2005;40:425&#x2013;428. doi: 10.1097/01.MPG.0000157914.40088.31.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.MPG.0000157914.40088.31</ArticleId><ArticleId IdType="pubmed">15795588</ArticleId></ArticleIdList></Reference><Reference><Citation>Tu Y., Abell T.L., Raj S.R., Mar P.L. Mechanisms and management of gastrointestinal symptoms in postural orthostatic tachycardia syndrome. Neurogastroenterol. Motil. 2020;32:e14031. doi: 10.1111/nmo.14031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nmo.14031</ArticleId><ArticleId IdType="pubmed">33140561</ArticleId></ArticleIdList></Reference><Reference><Citation>Park K.J., Singer W., Sletten D.M., Low P.A., Bharucha A.E. Gastric emptying in postural tachycardia syndrome: A preliminary report. Clin. Auton. Res. 2013;23:163&#x2013;167. doi: 10.1007/s10286-013-0193-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10286-013-0193-y</ArticleId><ArticleId IdType="pmc">PMC3737368</ArticleId><ArticleId IdType="pubmed">23708963</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell D.S., Bell K.M., Cheney P.R. Primary Juvenile Fibromyalgia Syndrome and Chronic Fatigue Syndrome in Adolescents. Clin. Infect. Dis. 1994;18((Suppl._1)):S21&#x2013;S23. doi: 10.1093/clinids/18.Supplement_1.S21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/clinids/18.Supplement_1.S21</ArticleId><ArticleId IdType="pubmed">8148447</ArticleId></ArticleIdList></Reference><Reference><Citation>Mack K.J., Johnson J.N., Rowe P.C. Orthostatic intolerance and the headache patient. Semin. Pediatr. Neurol. 2010;17:109&#x2013;116. doi: 10.1016/j.spen.2010.04.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.spen.2010.04.006</ArticleId><ArticleId IdType="pubmed">20541103</ArticleId></ArticleIdList></Reference><Reference><Citation>Hakim A., De Wandele I., O&#x2019;Callaghan C., Pocinki A., Rowe P. Chronic fatigue in Ehlers-Danlos syndrome-Hypermobile type. Am. J. Med. Genet. C Semin. Med. Genet. 2017;175:175&#x2013;180. doi: 10.1002/ajmg.c.31542.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajmg.c.31542</ArticleId><ArticleId IdType="pubmed">28186393</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowe P. Fatigue and myalgic encephalomyelitis/chronic fatigue syndrome. In: Neinstein L., editor. Neinstein&#x2019;s Adolescent and Young Adult Health Care, 7 ed. Wolters Kluwer; Philadelphia, PA, USA: 2021.</Citation></Reference><Reference><Citation>Nijs J., De Meirleir K., Truyen S. Hypermobility in Patients with Chronic Fatigue Syndrome: Preliminary Observations. J. Musculoskelet. Pain. 2004;12:9&#x2013;17. doi: 10.1300/J094v12n01_03.</Citation><ArticleIdList><ArticleId IdType="doi">10.1300/J094v12n01_03</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowe P.C., Barron D.F., Calkins H., Maumenee I.H., Tong P.Y., Geraghty M.T. Orthostatic intolerance and chronic fatigue syndrome associated with Ehlers-Danlos syndrome. J. Pediatr. 1999;135:494&#x2013;499. doi: 10.1016/S0022-3476(99)70173-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-3476(99)70173-3</ArticleId><ArticleId IdType="pubmed">10518084</ArticleId></ArticleIdList></Reference><Reference><Citation>De Wandele I., Rombaut L., De Backer T., Peersman W., Da Silva H., De Mits S., De Paepe A., Calders P., Malfait F. Orthostatic intolerance and fatigue in the hypermobility type of Ehlers-Danlos Syndrome. Rheumatology. 2016;55:1412&#x2013;1420. doi: 10.1093/rheumatology/kew032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kew032</ArticleId><ArticleId IdType="pubmed">27094596</ArticleId></ArticleIdList></Reference><Reference><Citation>De Wandele I., Calders P., Peersman W., Rimbaut S., De Backer T., Malfait F., De Paepe A., Rombaut L. Autonomic symptom burden in the hypermobility type of Ehlers-Danlos syndrome: A comparative study with two other EDS types, fibromyalgia, and healthy controls. Semin. Arthritis Rheum. 2014;44:353&#x2013;361. doi: 10.1016/j.semarthrit.2014.05.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2014.05.013</ArticleId><ArticleId IdType="pubmed">24968706</ArticleId></ArticleIdList></Reference><Reference><Citation>De Wandele I., Rombaut L., Leybaert L., Van de Borne P., De Backer T., Malfait F., De Paepe A., Calders P. Dysautonomia and its underlying mechanisms in the hypermobility type of Ehlers&#x2013;Danlos syndrome. Semin. Arthritis Rheum. 2014;44:93&#x2013;100. doi: 10.1016/j.semarthrit.2013.12.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2013.12.006</ArticleId><ArticleId IdType="pubmed">24507822</ArticleId></ArticleIdList></Reference><Reference><Citation>Heffez D.S., Ross R.E., Shade-Zeldow Y., Kostas K., Shah S., Gottschalk R., Elias D.A., Shepard A., Leurgans S.E., Moore C.G. Clinical evidence for cervical myelopathy due to Chiari malformation and spinal stenosis in a non-randomized group of patients with the diagnosis of fibromyalgia. Eur. Spine J. 2004;13:516&#x2013;523. doi: 10.1007/s00586-004-0672-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00586-004-0672-x</ArticleId><ArticleId IdType="pmc">PMC3476600</ArticleId><ArticleId IdType="pubmed">15083352</ArticleId></ArticleIdList></Reference><Reference><Citation>Reznikov L.R., Norris M.H., Vashisht R., Bluhm A.P., Li D., Liao Y.-S.J., Brown A., Butte A.J., Ostrov D.A. Identification of antiviral antihistamines for COVID-19 repurposing. Biochem. Biophys. Res. Commun. 2021;538:173&#x2013;179. doi: 10.1016/j.bbrc.2020.11.095.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2020.11.095</ArticleId><ArticleId IdType="pmc">PMC7713548</ArticleId><ArticleId IdType="pubmed">33309272</ArticleId></ArticleIdList></Reference><Reference><Citation>Malone R.W., Tisdall P., Fremont-Smith P., Liu Y., Huang X.P., White K.M., Ricke D.O. COVID-19: Famotidine, Histamine, Mast Cells, and Mechanisms. Res. Sq. 2020;12:633680. doi: 10.3389/fphar.2021.633680.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2021.633680</ArticleId><ArticleId IdType="pmc">PMC8021898</ArticleId><ArticleId IdType="pubmed">33833683</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu M.-L., Liu F.-L., Sun J., Li X., He X.-Y., Zheng H.-Y., Zhou Y.-H., Yan Q., Chen L., Yu G.-Y., et al. SARS-CoV-2-triggered mast cell rapid degranulation induces alveolar epithelial inflammation and lung injury. Signal Transduct. Target. Ther. 2021;6:428. doi: 10.1038/s41392-021-00849-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-021-00849-0</ArticleId><ArticleId IdType="pmc">PMC8677926</ArticleId><ArticleId IdType="pubmed">34921131</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>